Form 4: Century Therapeutics Executive Sells Shares for Tax Withholding

Century Therapeutics reports a Form 4 filing detailing the sale of shares by Chief Technology and Manufacturing Officer Gregory Russotti to cover tax withholding obligations.

Summary

• Gregory Russotti, Chief Technology and Manufacturing Officer at Century Therapeutics, Inc., reported a transaction on June 8, 2026.
• The transaction involved the sale of 111 shares of common stock at a price of $2.111 per share.
• These sales were executed automatically to cover tax withholding obligations related to the vesting of restricted stock units.
• Following this transaction, Russotti directly beneficially owns 514,903 shares.
• Additionally, Russotti indirectly beneficially owns 92,773 shares through the Gregory Russotti 2021 Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a routine transaction for tax withholding purposes and does not indicate a change in the executive's long-term conviction in the company.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership due to tax obligations.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executives and significant shareholders regarding changes in their holdings. This specific filing indicates a routine event related to equity compensation rather than a strategic business decision.

Stakeholder Impact

• Shareholders: The sale is automatic and not discretionary, intended to cover tax obligations, thus it is unlikely to have a significant direct impact on the share price or market perception beyond routine disclosure.

Key Dates

Keywords

Form 4, SEC Filing, Century Therapeutics, Gregory Russotti, Stock Sale, Tax Withholding, Restricted Stock Units, Beneficial Ownership